Proliferative activities of non-palpable breast cancer detected by mammography

对乳房x光检查发现的非可触性乳腺癌的增殖活动进行评估，以使其手术治疗合理化。研究了p34^<cdc2>、c-erbB-2和p53的过表达。western blotting结果显示，p34^<cdc2>在14/58（24.1%）的可触及乳腺癌中过表达。12例正常乳腺组织未见p34^<cdc2>过表达（0%）。因此，我们认为p34^<cdc2>的过表达表明乳腺癌组织具有增殖活性。随后使用石蜡包埋切片对p34^<cdc2>过表达进行免疫染色。在5 × 400视野内评估p34^<cdc2>染色阳性细胞在观察细胞中的比例。6例纤维囊性疾病中有1例（16.7%），16例（100%）不可触及乳腺癌中有16例（100%），8例（100%）可触及乳腺癌中有8例（100%）p34^<cdc2>染色细胞阳性比例超过2%。6例纤维囊性疾病中有1例（16.7%）、16例非可腭性乳腺癌中有6例（37.5%）、8例可触性乳腺癌中有7例（87.5%）p34^<cdc2>染色细胞阳性比例超过4%。在4例（0%）纤维囊性疾病中，c-erbB-2免疫染色均无阳性。相比之下，16例（50%）不可触及的乳腺癌中有8例c-erbB-2免疫染色阳性。4例纤维囊性疾病中1例（25%）p53免疫染色阳性，16例不可触及乳腺癌中3例（20%）p53免疫染色阳性。综上所述，p34^<cdc2>的过表达可能反映了乳腺癌的高增殖活性。与纤维囊性疾病相比，不可摸性乳腺癌p34^<cdc2>染色细胞阳性比例较高，c-erbB-2免疫染色强度更强，提示乳房x光检查发现的不可摸性乳腺癌是手术治疗的候选。

Proliferative activities of non-palpable breast cancer detected by mammography were evaluated in order to rationalize surgical treatment for them. Overexpression of p34^<cdc2>, c-erbB-2 and p53 have been studied. Overexpression of p34^<cdc2> was observed in 14/58 (24.1%) of the palpable breast cancers by western blotting. In contrast, overexpression of p34^<cdc2> was not observed in 12 normal breast tissues (0%). Therefore it was considered that overexpression of p34^<cdc2> indicated proliferative activities of breast cancerous tissues. Subsequently immunostaining for p34^<cdc2> overexpression was carried out using paraffin-embedded sections. Proportions of positive p34^<cdc2> staining cells among observed cells were assessed in five x400 fields. Ratios of positive p34^<cdc2> staining cells were more than 2 % in 1 of 6 (16.7%) fibrocystic diseases, 16 of 16 (100%) non-palpable breast cancers and 8 of 8 (100%) palpable breast cancers. Ratios of positive p34^<cdc2> staining cells were more than 4 % in 1 of 6 (16.7%) fibrocystic diseases, 6 of 16 (37.5%) non-palable breast cancers and 7 of 8 (87.5%) palpable breast cancers. In none of 4 (0%) fibrocystic diseases the c-erbB-2 immunostaining were positive. In contrast, c-erbB-2 immunostainings were positive in 8 of 16 (50%) non-palpable breast cancers. The p53 immunostainings were positive in one of 4 (25%) fibrocystic diseases and 3 of 16 (20%) non-palpable breast cancers. In conclusion, it is likely that overexpression of p34^<cdc2> reflects high proliferative activities of breast cancer. Higher ratios of positive p34^<cdc2> staining cells and stronger intensity of c-erbB-2 immunostaining in non-palpable breast cancer compared with fibrocystic disease indicate that non-palpable breast cancer detected by mammography is candidate for surgical therapy.